Pre-Made Valanafusp Alfa Biosimilar, Fusion Protein targeting INSR fused with human IDUA (iduronidase, alpha-L-) (1:2): Recombinant therapeutic protein targeting CD220/HHF5 for drug discovery and mechanism of action (MOA) research

Pre-Made Valanafusp Alfa Biosimilar, Fusion Protein targeting INSR fused with human IDUA (iduronidase, alpha-L-) (1:2): Recombinant therapeutic protein targeting CD220/HHF5 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Valanafusp alpha, is a blood–brain barrier (BBB)-penetrating IgG- α-L-iduronidase fusion protein, where the IgG domain is a monoclonal antibody (MAb) that targets the human insulin receptor (HIR). Mucopolysaccharidosis type I (MPSI) is caused by mutations in the gene encoding the a-L-iduronidase (IDUA) lysosomal enzyme and the majority of MPSI patients have severe central nervous system (CNS) involvement. The HIRMAb domain of valanafusp alpha binds to the endogenous insulin receptor on the human BBB to trigger receptor-mediated transport across the BBB, and acts as a molecular Trojan horse to ferry the fused IDUA into the brain of patients with MPSI.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1043-1mg	1mg	3090
GMP-Bios-INN-1043-10mg	10mg	Inquiry
GMP-Bios-INN-1043-100mg	100mg	Inquiry
GMP-Bios-INN-1043-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Valanafusp Alfa Biosimilar, Fusion Protein targeting INSR fused with human IDUA (iduronidase, alpha-L-) (1:2): Recombinant therapeutic protein targeting CD220/HHF5
INN Name	Valanafusp Alfa
Target	INSR
Format	Fusion Protein
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	ArmaGen, Inc. (Calabas CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0